No Data
No Data
A Struggling Pfizer Looks for Help From a Wall Streeter -- Barrons.com
By Josh Nathan-Kazis Andrew Baum, a Citigroup drug-company analyst and its head of global healthcare, hasn't had a Buy rating on Pfizer shares for over a decade, and he has pulled his target price do
Express News | NYSE Order Imbalance 331307.0 Shares on Buy Side
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
Friday, Aethlon Medical Inc (NASDAQ:AEMD) released results from an in vitro binding study of its Hemopurifier in removing extracellular vesicles (EVs) from plasma. Extracellular vesicles contribute to
Merck's (NYSE:MRK) Investors Will Be Pleased With Their Notable 90% Return Over the Last Three Years
The MSD (MRK.US) KeyTruda combined chemotherapy-adjuvant treatment of high-risk endometrial cancer phase III study did not reach the main end
The Zhitong Finance App learned that on May 9, MSD (MRK.US) announced that the PD-1 inhibitor Keytruda (pabolizumab) combined chemotherapy (with or without radiotherapy) as adjuvant treatment for newly diagnosed and surgically treated high-risk endometrial cancer patients did not reach the main end point of disease-free survival (DFS). In the US, Keytruda has been approved for two indications for endometrial cancer treatment. Keytruda has a comprehensive clinical development plan for endometrial cancer treatment, including NRG-GY018
Drugmakers in Medicare Price Negotiations Spent Less on Research Than on Shareholder Payments, Marketing and Overhead: Report
No Data
Xiaobie : how do you read TRIPLE?